ES2725463T3 - Tratamientos combinados con anticuerpos anti-CD40 - Google Patents

Tratamientos combinados con anticuerpos anti-CD40 Download PDF

Info

Publication number
ES2725463T3
ES2725463T3 ES15750051T ES15750051T ES2725463T3 ES 2725463 T3 ES2725463 T3 ES 2725463T3 ES 15750051 T ES15750051 T ES 15750051T ES 15750051 T ES15750051 T ES 15750051T ES 2725463 T3 ES2725463 T3 ES 2725463T3
Authority
ES
Spain
Prior art keywords
antibody
seq
tumor
antigen binding
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15750051T
Other languages
English (en)
Spanish (es)
Inventor
Peter Ellmark
Per Norlen
Niina Veitonmäki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2725463(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1414270.7A external-priority patent/GB201414270D0/en
Priority claimed from GBGB1507541.9A external-priority patent/GB201507541D0/en
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Application granted granted Critical
Publication of ES2725463T3 publication Critical patent/ES2725463T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15750051T 2014-08-12 2015-08-12 Tratamientos combinados con anticuerpos anti-CD40 Active ES2725463T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1414270.7A GB201414270D0 (en) 2014-08-12 2014-08-12 Antibodies
GB201422614 2014-12-18
GBGB1507541.9A GB201507541D0 (en) 2015-05-01 2015-05-01 Antibodies
PCT/EP2015/068598 WO2016023960A1 (en) 2014-08-12 2015-08-12 Combination therapies with anti cd40 antibodies

Publications (1)

Publication Number Publication Date
ES2725463T3 true ES2725463T3 (es) 2019-09-24

Family

ID=53836090

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15750051T Active ES2725463T3 (es) 2014-08-12 2015-08-12 Tratamientos combinados con anticuerpos anti-CD40

Country Status (25)

Country Link
US (3) US11149090B2 (enExample)
EP (3) EP3552665A3 (enExample)
JP (1) JP6654187B2 (enExample)
KR (1) KR102443258B1 (enExample)
CN (3) CN114099671A (enExample)
AU (1) AU2015303164B2 (enExample)
CA (1) CA2957146A1 (enExample)
CL (1) CL2017000335A1 (enExample)
CO (1) CO2017001317A2 (enExample)
CR (1) CR20170096A (enExample)
DK (1) DK3180087T3 (enExample)
EA (1) EA201790339A1 (enExample)
EC (1) ECSP17008984A (enExample)
ES (1) ES2725463T3 (enExample)
IL (1) IL250512B (enExample)
MA (1) MA47472A (enExample)
MX (1) MX382549B (enExample)
NI (1) NI201700015A (enExample)
PE (1) PE20170680A1 (enExample)
PH (1) PH12017500229A1 (enExample)
SG (1) SG11201701070WA (enExample)
SV (1) SV2017005380A (enExample)
UA (1) UA119783C2 (enExample)
WO (1) WO2016023960A1 (enExample)
ZA (1) ZA201701126B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及/或 lag3結合劑
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
EP3455262A4 (en) * 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EA201990293A1 (ru) 2016-07-14 2019-07-31 Генмаб А/С Мультиспецифичные антитела против cd40 и cd137
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
EP3532505A4 (en) 2016-10-25 2019-12-25 Urogen Pharma Ltd. BODY CAVES IMMUNODULATING TREATMENTS
EP3534951A4 (en) * 2016-11-02 2020-09-23 Apexigen, Inc. ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
EP3569616B1 (en) * 2017-01-13 2021-09-29 Taizhou Hanzhong Biopharmaceutics, Inc. Monoclonal antibody against pd-1 and applications thereof
JP2020510673A (ja) * 2017-03-03 2020-04-09 ヤンセン バイオテツク,インコーポレーテツド がんの治療のための低分子csf−1r阻害剤とcd40に特異的に結合するアゴニスト抗体とを含む併用療法
CA3071217A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh Hsp70 based combination therapy
BR112020018761A2 (pt) * 2018-03-13 2020-12-29 Hibercell, Inc. Imunoterapia combinada com beta-glucano e agonista de cd40
EP3807320A4 (en) * 2018-06-12 2022-03-23 BioNTech US Inc. POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
JP7155403B2 (ja) * 2018-08-20 2022-10-18 ファイザー・インク 抗gdf15抗体、組成物および使用の方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020102739A1 (en) 2018-11-15 2020-05-22 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
AU2019383548A1 (en) 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates
EP3892634A4 (en) * 2018-11-30 2022-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20230174658A1 (en) * 2019-05-28 2023-06-08 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd40 antibody
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230055235A1 (en) * 2019-12-27 2023-02-23 Interoligo Corporation. Anti-cancer immunotherapeutic composition for treating cancer
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER
CN118201636A (zh) * 2021-10-26 2024-06-14 萨摩亚商柏沛生医股份有限公司 抗癌症及感染性疾病的组合疗法
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1996006641A1 (en) 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
ATE295882T1 (de) 2000-12-12 2005-06-15 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
ES2285118T5 (es) 2002-05-17 2012-09-21 Alligator Bioscience Ab Un método para el desarrollo molecular in vitro de una función proteica.
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
CA2564296A1 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ATE485057T1 (de) 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
AU2009286247A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a CD40 agonist to a tumor draining lymph node of a subject
ES2581516T3 (es) * 2009-09-16 2016-09-06 The Chemours Company Fc, Llc Aparato enfriador que contiene trans-1,1,1,4,4,4-hexafluoro-2-buteno y procedimientos para producir enfriamiento en él
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック, インコーポレイテッド Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
EA201600474A1 (ru) 2013-12-20 2016-11-30 Ф. Хоффманн-Ля Рош Аг Комбинированная терапия с использованием антитела к ang2 и агониста cd40
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
MA53243A (fr) 2015-04-17 2021-06-23 Bristol Myers Squibb Co Compositions comprenant une combinaison de ipilimumab et nivolumab
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
CN107771184B (zh) 2015-06-29 2022-11-01 百时美施贵宝公司 针对cd40的抗体
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity

Also Published As

Publication number Publication date
US11149090B2 (en) 2021-10-19
UA119783C2 (uk) 2019-08-12
BR112017002729A2 (pt) 2018-02-27
JP2017524715A (ja) 2017-08-31
WO2016023960A1 (en) 2016-02-18
KR102443258B1 (ko) 2022-09-14
AU2015303164A1 (en) 2017-03-09
ECSP17008984A (es) 2017-05-31
MX382549B (es) 2025-03-13
AU2015303164B2 (en) 2020-10-29
CR20170096A (es) 2017-06-15
MX2017001864A (es) 2017-08-02
CN114099671A (zh) 2022-03-01
MA47472A (fr) 2019-12-18
IL250512A0 (en) 2017-03-30
DK3180087T3 (da) 2019-05-13
EP3552665A3 (en) 2019-12-18
NZ729270A (en) 2024-03-22
KR20170041790A (ko) 2017-04-17
EP3180087A1 (en) 2017-06-21
SV2017005380A (es) 2018-09-14
US20240132609A1 (en) 2024-04-25
US20240228643A9 (en) 2024-07-11
EP4653463A2 (en) 2025-11-26
EP3552665A2 (en) 2019-10-16
IL250512B (en) 2021-08-31
PE20170680A1 (es) 2017-06-14
CL2017000335A1 (es) 2017-08-11
CN106573981A (zh) 2017-04-19
CO2017001317A2 (es) 2017-08-10
SG11201701070WA (en) 2017-03-30
NI201700015A (es) 2017-05-12
EP3180087B1 (en) 2019-03-13
CN119280407A (zh) 2025-01-10
US20210403589A1 (en) 2021-12-30
ZA201701126B (en) 2025-08-27
CA2957146A1 (en) 2016-02-18
PH12017500229A1 (en) 2017-07-10
US20170226217A1 (en) 2017-08-10
JP6654187B2 (ja) 2020-02-26
EA201790339A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
ES2725463T3 (es) Tratamientos combinados con anticuerpos anti-CD40
JP7214238B2 (ja) 腫瘍療法のためのil-12とt細胞阻害分子遮断薬とを含む医薬組成物
ES3006183T3 (en) Antibody molecules that bind pd-l1 and cd137
ES2954851T3 (es) Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso
ES2905890T3 (es) Anticuerpos anti-4-1BB humano y usos de los mismos
ES2858091T3 (es) Moléculas de unión que se unen a PD-L1 y LAG-3
ES3010640T3 (en) Lag-3 binding members
ES3035107T3 (en) Mesothelin and cd137 binding molecules
ES2910365T3 (es) Nuevos polipéptidos biespecíficos contra CD137
ES3027407T3 (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
ES2992478T3 (es) Nuevos anticuerpos anti-PD-1
ES2948807T3 (es) Anticuerpos anti CD3, moléculas de unión a antígeno biespecíficas que se unen a CD3 y a CD20 y usos de los mismos
ES2984950T3 (es) Anticuerpos específicos para CD3 y sus usos
CN111201038A (zh) Psgl-1拮抗剂及其用途
CN113993547A (zh) 结合muc16和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
JP2024522234A (ja) 新規な併用療法及びその使用
US20240415828A1 (en) Tlr7 agonist and combinations for cancer treatment
BR112017002729B1 (pt) Terapia de combinação kit para tratar um tumor sólido em um indivíduo, anticorpo ou porção de ligação a antígeno do mesmo, uso e composição farmacêutica
KR20250025384A (ko) Ceacam5 및 cd47에 대한 이중특이적 항체 및 ceacam5 및 cd3에 대한 이중특이적 항체의 조합 요법
HK40120378A (zh) 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
CN120225559A (zh) 新型抗itgb8抗体及其用途
HK40113788A (zh) 抗cd39抗体及其用途
HK40079159A (en) Methods of treating cancer with anti-pd-1 antibodies